generic_name,reasoning,less_determination,binary_determination,less_determination_score,binary_determination_score
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,"The provided drug label for MIRCERA (methoxy polyethylene glycol-epoetin beta) does not contain any sections or sentences that discuss ototoxicity, auditory risks, or ototoxic reactions. The label focuses on other potential adverse effects and warnings, such as increased risks of death, myocardial infarction, stroke, venous thromboembolism, tumor progression, hypertension, seizures, and serious allergic reactions. There is no mention of ototoxicity or auditory risks associated with the use of MIRCERA in the provided document.",No,No,1,1
RIFAPENTINE,"The provided drug label for PRIFTIN (rifapentine) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on other adverse reactions, such as hepatotoxicity, hypersensitivity, severe cutaneous adverse reactions, and drug interactions. 
 

 Here is a summary of the relevant sections that were reviewed for ototoxicity and auditory risks:
 

 1. **Warnings and Precautions**:
  - **Hepatotoxicity**: Discusses liver injury risks.
  - **Hypersensitivity and Related Reactions**: Mentions various hypersensitivity reactions but does not include ototoxicity.
  - **Severe Cutaneous Adverse Reactions**: Focuses on skin reactions.
  - **Relapse in the Treatment of Active Pulmonary Tuberculosis**: Discusses relapse risks in TB treatment.
  - **Drug Interactions**: Highlights interactions with other drugs metabolized by CYP450 enzymes.
  - **Discoloration of Body Fluids**: Notes discoloration of body fluids but not auditory risks.
  - **Clostridioides difficile–Associated Diarrhea**: Discusses risks of CDAD.
  - **Porphyria**: Advises against use in patients with porphyria.
 

 2. **Adverse Reactions**:
  - **Clinical Trials Experience**: Lists common adverse reactions such as anemia, lymphopenia, hemoptysis, neutropenia, cough, thrombocytosis, increased sweating, increased ALT, increased AST, back pain, rash, anorexia, arthralgia, increased blood urea, and headache. No mention of ototoxicity or auditory risks.
  - **Postmarketing Experience**: Notes severe cutaneous adverse reactions but does not mention ototoxicity.
 

 3. **Drug Interactions**:
  - Discusses interactions with protease inhibitors, reverse transcriptase inhibitors, hormonal contraceptives, and drugs metabolized by cytochrome P450 enzymes. No mention of ototoxicity.
 

 4. **Use in Specific Populations**:
  - **Pregnancy**: Discusses risks to the fetus but not auditory risks.
  - **Lactation**: Advises monitoring infants for hepatotoxicity.
  - **Pediatric Use**: Notes safety and effectiveness in children for latent TB but does not mention ototoxicity.
  - **Geriatric Use**: No specific mention of ototoxicity.
 

 5. **Clinical Studies**:
  - Describes the outcomes of clinical trials for active pulmonary tuberculosis and latent tuberculosis infection. No mention of ototoxicity.
 

 6. **Patient Counseling Information**:
  - Advises on treatment adherence, hypersensitivity reactions, severe cutaneous adverse reactions, hepatitis, drug interactions, discoloration of body fluids, administration with food, lactation, and contraception. No mention of ototoxicity.
 

 In conclusion, the drug label for PRIFTIN does not associate the drug with ototoxicity or auditory risks. There are no mentions or discussions of ototoxic reactions in the provided sections of the drug label.",No,No,1,1
CLOFARABINE,"The provided drug label for Clolar (clofarabine) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label extensively covers various other adverse reactions, warnings, and precautions, but there is no specific information related to ototoxicity or auditory risks associated with the drug. Therefore, based on the provided label, Clolar is not associated with or known to cause ototoxicity or auditory risks.",No,No,1,1
I.V. FAT EMULSION,"The provided drug label for Intralipid does not mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and other relevant clinical information related to the use of Intralipid as a lipid injectable emulsion for parenteral nutrition. There is no specific information or warnings related to ototoxicity or auditory risks associated with this drug.",No,No,1,1
CLOTRIMAZOLE,"The provided drug label for Clotrimazole Lozenges USP 10 mg does not contain any sections or sentences that discuss ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the drug's indications, usage, contraindications, warnings, precautions, adverse reactions, dosage, and administration, but it does not mention any risks or effects related to hearing or the auditory system. Therefore, there is no information indicating that the drug itself is associated with or causes ototoxicity risks.",No,No,1,1
AMMONIA N 13,"The drug label for Ammonia N 13 Injection does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the provided drug label that discuss these specific concerns. Therefore, based on the provided information, Ammonia N 13 Injection is not associated with or known to cause ototoxicity or auditory risks.",No,No,1,1
MILNACIPRAN HCL,"The provided drug label for Milnacipran Hydrochloride does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. The sections discussing adverse reactions, warnings, and precautions do not include any information about hearing loss, tinnitus, or other auditory issues directly associated with the drug. 
 

 Here is a summary of the relevant sections that were reviewed for ototoxicity and auditory risks:
 

 1. **Adverse Reactions (6.1, 6.2)**:
  - The most frequently occurring adverse reactions include nausea, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, vomiting, palpitations, heart rate increased, dry mouth, and hypertension. No mention of ototoxicity or auditory risks.
  - Post-marketing experience includes various adverse reactions, but none related to ototoxicity or auditory risks.
 

 2. **Warnings and Precautions (5)**:
  - Discusses risks such as suicidality, serotonin syndrome, elevated blood pressure and heart rate, seizures, hepatotoxicity, discontinuation symptoms, hyponatremia, increased risk of bleeding, activation of mania, history of dysuria, sexual dysfunction, angle closure glaucoma, and concomitant use with alcohol. No mention of ototoxicity or auditory risks.
 

 3. **Clinical Trials Experience (6.1)**:
  - Adverse reactions leading to discontinuation and most common adverse reactions in placebo-controlled trials are listed, but none related to ototoxicity or auditory risks.
 

 4. **Post-marketing Experience (6.2)**:
  - Lists additional adverse reactions identified from spontaneous reports, including blood and lymphatic system disorders, cardiac disorders, eye disorders, endocrine disorders, gastrointestinal disorders, hepatobiliary disorders, metabolism and nutrition disorders, musculoskeletal and connective tissue disorders, nervous system disorders, psychiatric disorders, renal and urinary disorders, reproductive system and breast disorders, skin disorders, and vascular disorders. No mention of ototoxicity or auditory risks.
 

 5. **Drug Interactions (7)**:
  - Discusses interactions with MAOIs, serotonergic drugs, triptans, catecholamines, CNS-active drugs, cardiovascular agents, and drugs that interfere with hemostasis. No mention of ototoxicity or auditory risks.
 

 6. **Use in Specific Populations (8)**:
  - Discusses use in pregnancy, lactation, pediatric use, geriatric use, and patients with renal or hepatic impairment. No mention of ototoxicity or auditory risks.
 

 In conclusion, the drug label for Milnacipran Hydrochloride does not associate the drug with ototoxicity or auditory risks. There are no reported cases or warnings related to hearing loss or other auditory issues in the provided document.",No,No,1,1
LIDOCAINE HCL,"The provided drug label for XYLOCAINE®- MPF (LIDOCAINE HCl INJECTION, USP) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the pharmacology, indications, contraindications, warnings, precautions, adverse reactions, and dosage of lidocaine HCl. 
 

 Here is a summary of the relevant sections that might indirectly relate to auditory risks, but none of these sections explicitly state that the drug itself is associated with or causes ototoxicity:
 

 1. **Central Nervous System (CNS) Manifestations**:
  - ""CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest.""
  - **Summary**: Tinnitus (ringing in the ears) is mentioned as a possible CNS manifestation, but it does not explicitly state that the drug causes ototoxicity.
 

 2. **Warnings and Precautions**:
  - The label includes extensive warnings and precautions about the use of the drug, particularly focusing on the potential for systemic toxicity, cardiovascular effects, and CNS effects.
  - **Summary**: There is no specific mention of ototoxicity or auditory risks directly associated with the drug.
 

 3. **Adverse Reactions**:
  - ""Adverse experiences following the administration of lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient.""
  - **Summary**: The adverse reactions section does not specifically mention ototoxicity or auditory risks.
 

 4. **Information for Patients**:
  - ""When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of epidural anesthesia.""
  - **Summary**: This section does not mention ototoxicity or auditory risks.
 

 In conclusion, the drug label for XYLOCAINE®- MPF (LIDOCAINE HCl INJECTION, USP) does not provide any specific information or warnings about ototoxicity, auditory risks, or ototoxic reactions directly associated with the drug. The mention of tinnitus as a CNS manifestation is the closest reference to an auditory issue, but it does not explicitly link the drug to ototoxicity.",No,No,1,1
BIVALIRUDIN,"The provided drug label for Bivalirudin RTU Injection does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the label that discuss these specific adverse effects. Therefore, based on the information provided in the drug label, Bivalirudin RTU Injection is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1
TROFINETIDE,"The provided drug label for DAYBUE (trofinetide) does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the label that associate the drug with ototoxicity or auditory risks. The label primarily discusses the indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, drug interactions, use in specific populations, and clinical pharmacology of DAYBUE, but it does not address any concerns related to hearing or ear health.",No,No,1,1
FLOTUFOLASTAT F-18,"The drug label for POSLUMA (flotufolastat F 18) does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the provided drug label that discuss these specific adverse effects. Therefore, it can be concluded that the drug itself is not associated with or does not cause ototoxicity risks based on the information provided in the label.",No,No,1,1
MORPHINE SULFATE,"The provided drug label for Morphine Sulfate Oral Solution does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label extensively covers various risks, warnings, precautions, and adverse reactions associated with the use of morphine sulfate, but it does not include any information related to ototoxicity or auditory risks.
 

 To summarize:
 

 - **Ototoxicity and Auditory Risks**: There is no mention of ototoxicity or auditory risks associated with the use of Morphine Sulfate Oral Solution in the provided drug label.
 - **Ototoxic Reactions**: The label does not discuss any ototoxic reactions caused by Morphine Sulfate Oral Solution.
 

 Therefore, based on the provided drug label, Morphine Sulfate Oral Solution is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1
IODINATED I-131 ALBUMIN,"The drug label for MEGATOPE (iodinated I-131 albumin) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. Here is a summary of the relevant sections that might indirectly relate to such concerns, although none directly associate the drug with ototoxicity:
 

 1. **Warnings**:
  - ""Aseptic meningitis and pyrogenic reactions have been reported following cisternography with MEGATOPE. The safety and effectiveness of MEGATOPE for cisternography have not been established. MEGATOPE is not approved for this use.""
  - **Summary**: This warning does not mention ototoxicity. It states that aseptic meningitis and pyrogenic reactions have been reported, but these are not directly related to auditory risks or ototoxicity.
 

 2. **Adverse Reactions**:
  - ""The following adverse reactions have been identified with the use of radioiodinated albumin products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.""
  - **Summary**: This section does not list specific adverse reactions related to ototoxicity. It mentions that adverse reactions are reported but does not specify any auditory risks or ototoxic reactions.
 

 3. **Precautions**:
  - ""In the use of any radioactive material, care should be taken to minimize radiation exposure to the patient and healthcare providers consistent with proper patient management.""
  - **Summary**: This general precaution advises minimizing radiation exposure but does not specifically mention ototoxicity or auditory risks.
 

 4. **Pregnancy**:
  - ""Iodine-131 crosses the placenta and can permanently impair fetal thyroid function.""
  - **Summary**: This statement addresses fetal thyroid function impairment but does not mention ototoxicity or auditory risks.
 

 5. **Nursing Mothers**:
  - ""Iodine-131 is present in human milk. There are no data on the effect of iodinated I 131 albumin on the breastfed infant or milk production. Because of the potential for serious adverse reactions in the breastfed infant, including transient hypothyroidism, advise women not to breastfeed during treatment with MEGATOPE and for 80 days after the final dose.""
  - **Summary**: This section advises against breastfeeding due to potential adverse reactions, including transient hypothyroidism, but does not mention ototoxicity or auditory risks.
 

 In conclusion, the drug label for MEGATOPE does not provide any information or warnings specifically related to ototoxicity, auditory risks, or ototoxic reactions.",No,No,1,1
FOSPHENYTOIN,"The drug label for Fosphenytoin Sodium Injection does not explicitly mention ototoxicity or auditory risks as a primary concern. However, there are a few references to auditory-related adverse reactions. Here is a summary of those parts:
 

 1. **Section 6.1 Clinical Trials Experience:**
  - **Special Senses:**
  - ""Tinnitus"" was reported in 9% of patients treated with intravenous fosphenytoin sodium. This indicates that the drug itself was associated with tinnitus.
  - ""Diplopia"" was reported in 3% of patients treated with intravenous fosphenytoin sodium. This indicates that the drug itself was associated with diplopia.
  - ""Amblyopia"" was reported in 2% of patients treated with intravenous fosphenytoin sodium. This indicates that the drug itself was associated with amblyopia.
  - ""Deafness"" was reported in 2% of patients treated with intravenous fosphenytoin sodium. This indicates that the drug itself was associated with deafness.
 

 2. **Section 6.2 Post-marketing Experience:**
  - **Nervous System Disorders:**
  - ""Dyskinesia"" was reported during post-approval use of phenytoin or fosphenytoin. This indicates that the drug itself was associated with dyskinesia, although this is not directly related to auditory risks.
 

 3. **Section 7.2 Drugs Affected by Phenytoin or Fosphenytoin Sodium:**
  - **Neuromuscular blocking agents:**
  - Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. This indicates that the drug itself was associated with resistance to neuromuscular blocking agents, which is not directly related to auditory risks.
 

 In summary, the drug label indicates that fosphenytoin sodium is associated with tinnitus, diplopia, amblyopia, and deafness, but it does not explicitly discuss ototoxicity or auditory risks as primary concerns.",Less,Yes,2,1
ERTAPENEM SODIUM,"The drug label for INVANZ (ertapenem) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. Therefore, there are no parts of the label that discuss these specific concerns. 
 

 To summarize:
 - **Ototoxicity and auditory risks**: Not mentioned in the drug label.
 - **Ototoxic reactions**: Not mentioned in the drug label.
 

 Since there is no information provided on these topics, it can be concluded that the drug itself was not associated with or identified as causing ototoxicity risks based on the provided label.",No,No,1,1
ROPEGINTERFERON ALFA-2B,"The drug label for BESREMi (ropeginterferon alfa-2b-njft) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The provided text does not include any sections or sentences that discuss these specific risks or reactions. Therefore, there is no information indicating that BESREMi is associated with or causes ototoxicity or auditory risks.",No,No,1,1
GENTAMICIN SULFATE OPTH SOLUTION,"The provided drug label for Gentamicin Sulfate Ophthalmic Solution does not explicitly mention ototoxicity or auditory risks. The label primarily focuses on the ophthalmic use of the drug, its indications, contraindications, and potential adverse reactions related to ocular use. 
 

 Here is a summary of the relevant sections from the label:
 

 1. **General Warnings and Precautions**:
  - The label warns about the potential for overgrowth of nonsusceptible organisms, including fungi, with prolonged use of topical antibiotics. It also mentions the possibility of bacterial resistance to gentamicin. However, this does not directly relate to ototoxicity or auditory risks.
 

 2. **Adverse Reactions**:
  - The most frequently reported adverse reactions are ocular burning and irritation, non-specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia. Other rare adverse reactions include allergic reactions, thrombocytopenic purpura, and hallucinations. None of these adverse reactions are related to ototoxicity or auditory risks.
 

 3. **Pregnancy**:
  - The label mentions that gentamicin has been shown to depress body weights, kidney weights, and median glomerular counts in newborn rats when administered systemically to pregnant rats. However, this information pertains to systemic administration and does not directly address ototoxicity or auditory risks.
 

 4. **Carcinogenesis, Mutagenesis, Impairment of Fertility**:
  - The label states that there are no published carcinogenicity or impairment of fertility studies on gentamicin and that aminoglycoside antibiotics have been found to be non-mutagenic. This section does not discuss ototoxicity or auditory risks.
 

 In summary, the drug label for Gentamicin Sulfate Ophthalmic Solution does not provide any information or warnings specifically related to ototoxicity or auditory risks. The focus is on the ophthalmic use and potential ocular adverse reactions.",Most,No,1,1
TASIMELTEON,"The provided drug label for HETLIOZ (tasimelteon) does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the label that discuss these specific concerns. Therefore, based on the provided information, HETLIOZ is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1
DULOXETINE DELAYED-RELEASE CAPSULES,"The drug label for Duloxetine Delayed-Release Capsules mentions ototoxicity and auditory risks in the following sections:
 

 1. **Adverse Reactions in Adults**:
  - **Ear and Labyrinth Disorders**:
  - **Frequent**: vertigo
  - **Summary**: The drug itself was associated with vertigo as a frequent adverse reaction.
  - **Infrequent**: ear pain and tinnitus
  - **Summary**: The drug itself was associated with ear pain and tinnitus as infrequent adverse reactions.
 

 2. **Postmarketing Experience**:
  - **Adverse reactions reported since market introduction**:
  - Tinnitus (upon treatment discontinuation)
  - **Summary**: The drug itself was associated with tinnitus, particularly upon treatment discontinuation.
 

 In summary, Duloxetine Delayed-Release Capsules have been associated with vertigo, ear pain, and tinnitus as adverse reactions. Tinnitus has also been reported upon discontinuation of the drug.",Less,Yes,1,1
LEVOKETOCONAZOLE,"The provided drug label for RECORLEV (levoketoconazole) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on hepatotoxicity, QT prolongation, hypocortisolism, hypersensitivity reactions, and risks related to decreased testosterone. There is no information or warnings related to ototoxicity or auditory risks associated with the use of RECORLEV in the provided text.",No,No,1,1
TALIGLUCERASE ALFA,"The provided drug label for ELELYSO (taliglucerase alfa) does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the label that discuss these specific adverse effects. Therefore, based on the information given in the drug label, ELELYSO is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1
EPTINEZUMAB-JJMR,"The provided drug label for VYEPTI (eptinezumab-jjmr) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the drug's indications, dosage, administration, contraindications, warnings, adverse reactions, and clinical studies related to its use for the preventive treatment of migraine in adults. 
 

 To summarize:
 - **Indications and Usage**: VYEPTI is indicated for the preventive treatment of migraine in adults.
 - **Dosage and Administration**: Instructions on how to dilute and administer the drug intravenously.
 - **Contraindications**: VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or any of its excipients.
 - **Warnings and Precautions**: Focuses on hypersensitivity reactions, including anaphylaxis and angioedema.
 - **Adverse Reactions**: Lists common adverse reactions such as nasopharyngitis and hypersensitivity, but does not mention ototoxicity or auditory risks.
 - **Clinical Studies**: Describes the efficacy of VYEPTI in preventing migraines but does not discuss any auditory risks.
 

 Since there is no mention of ototoxicity or auditory risks in the provided drug label, it can be concluded that the drug itself was not associated with or caused any ototoxicity risk according to the information given.",No,No,1,1
HYDROXYZINE HCL,"The provided drug label for Hydroxyzine HCL 50mg Tablet does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. The label discusses various other side effects, contraindications, precautions, and adverse reactions, but there is no specific mention of ototoxicity or auditory risks associated with the use of hydroxyzine.
 

 To summarize:
 

 1. **Adverse Reactions**: The label lists several adverse reactions, including anticholinergic effects (dry mouth), central nervous system effects (drowsiness, involuntary motor activity, tremor, convulsions), cardiac effects (QT prolongation, Torsade de Pointes), allergic reactions, headache, hallucination, pruritus, rash, and urticaria. However, none of these reactions are related to ototoxicity or auditory risks.
 

 2. **Warnings and Precautions**: The label provides warnings about the potentiating action of hydroxyzine with CNS depressants, QT prolongation, and Torsade de Pointes, as well as caution in elderly patients and the risk of acute generalized exanthematous pustulosis (AGEP). Again, there is no mention of ototoxicity or auditory risks.
 

 3. **Overdosage**: The label describes symptoms of overdosage, such as hypersedation, convulsions, stupor, nausea, vomiting, and QT prolongation, but does not mention any auditory or ototoxic effects.
 

 In conclusion, the drug label for Hydroxyzine HCL 50mg Tablet does not associate the drug with ototoxicity or auditory risks.",No,No,1,1
IOFLUPANE I-123,"The provided drug label for DATSCAN (ioflupane I 123 injection) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the drug's indications, usage, dosage, administration, radiation safety, thyroid blocking, adverse reactions, and other specific precautions and instructions. There is no information or warnings related to ototoxicity or auditory risks associated with the use of DATSCAN.",No,No,1,1
TRAVOPROST OPHTHALMIC SOLUTION,"The provided drug label for Travoprost Ophthalmic Solution (Ionic Buffered Solution) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the ophthalmic use of the drug, its indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and specific population usage. 
 

 Here is a summary of the key sections reviewed for any mention of ototoxicity or auditory risks:
 

 1. **Indications and Usage**: No mention of ototoxicity or auditory risks.
 2. **Dosage and Administration**: No mention of ototoxicity or auditory risks.
 3. **Dosage Forms and Strengths**: No mention of ototoxicity or auditory risks.
 4. **Contraindications**: No mention of ototoxicity or auditory risks.
 5. **Warnings and Precautions**: Discusses pigmentation changes, eyelash changes, intraocular inflammation, macular edema, angle-closure glaucoma, bacterial keratitis, and use with contact lenses, but no mention of ototoxicity or auditory risks.
 6. **Adverse Reactions**: Lists ocular and non-ocular adverse reactions, but none related to ototoxicity or auditory risks.
 7. **Use in Specific Populations**: Discusses use in pregnancy, lactation, pediatric, geriatric, hepatic, and renal impairment, but no mention of ototoxicity or auditory risks.
 8. **Description**: Provides chemical and pharmacological details, but no mention of ototoxicity or auditory risks.
 9. **Clinical Pharmacology**: Discusses the mechanism of action and pharmacokinetics, but no mention of ototoxicity or auditory risks.
 10. **Nonclinical Toxicology**: Discusses carcinogenesis, mutagenesis, and impairment of fertility, but no mention of ototoxicity or auditory risks.
 11. **Clinical Studies**: Summarizes clinical study results, but no mention of ototoxicity or auditory risks.
 12. **How Supplied/Storage and Handling**: No mention of ototoxicity or auditory risks.
 13. **Patient Counseling Information**: Advises on pigmentation, eyelash changes, handling the container, seeking physician advice, use with contact lenses, and use with other ophthalmic drugs, but no mention of ototoxicity or auditory risks.
 

 In conclusion, the drug label for Travoprost Ophthalmic Solution does not associate the drug with ototoxicity or auditory risks, nor does it mention any ototoxic reactions.",No,No,1,1
ORLISTAT,"The drug label for XENICAL (orlistat) does not explicitly mention ototoxicity or auditory risks as a primary concern. However, there is a brief mention of an auditory-related adverse event in the context of other treatment-emergent adverse events. Here is the relevant information summarized:
 

 1. **Section 6.1 Clinical Trials - Other Adverse Clinical Events:**
  - **Hearing & Vestibular Disorders:**
  - **Otitis:** 
  - **Summary:** Otitis was reported in 4.3% of patients treated with XENICAL compared to 3.4% of patients treated with placebo during the first year of clinical trials. In the second year, otitis was reported in 2.9% of XENICAL-treated patients compared to 2.5% of placebo-treated patients.
  - **Association:** The drug itself was associated with a slightly higher incidence of otitis compared to placebo, but it is not explicitly stated that XENICAL caused otitis.
 

 No other sections of the drug label discuss ototoxicity, auditory risks, or ototoxic reactions directly associated with XENICAL. The mention of otitis is the only auditory-related adverse event noted, and while there is an association, causation is not definitively established.",Less,No,1,1
DARATUMUMAB,"The provided drug label for DARZALEX (daratumumab) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label extensively covers various aspects of the drug, including indications, dosage, administration, warnings, precautions, adverse reactions, and clinical studies, but there is no specific mention of ototoxicity or auditory risks associated with DARZALEX.
 

 To summarize:
 - **Ototoxicity and Auditory Risks**: The drug label does not discuss any ototoxicity or auditory risks.
 - **Ototoxic Reactions**: There are no mentions of ototoxic reactions caused by DARZALEX in the provided drug label.
 

 Therefore, based on the provided information, DARZALEX is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1
FLUOROESTRADIOL F 18,"The drug label for CERIANNA™ (fluoroestradiol F 18) does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the provided drug label that discuss these specific adverse effects. Therefore, it can be concluded that the drug itself is not associated with or known to cause ototoxicity or auditory risks based on the information provided in the label.",No,No,1,1
RAXIBACUMAB,"The drug label for Raxibacumab does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. Here is a summary of the relevant sections that might indirectly relate to such concerns, but none of them directly associate the drug with ototoxicity:
 

 1. **Adverse Reactions (Section 6.1)**:
  - **Ear and Labyrinth Disorders**: Vertigo was reported in less than 1.5% of subjects exposed to raxibacumab. However, vertigo is not explicitly linked to ototoxicity or auditory damage caused by the drug.
 

 2. **Warnings and Precautions (Section 5.1)**:
  - This section primarily discusses hypersensitivity and anaphylaxis, with no mention of ototoxicity or auditory risks.
 

 3. **Clinical Trials Experience (Section 6.1)**:
  - The safety of raxibacumab was studied in healthy volunteers, and the most frequently reported adverse reactions included rash, pain in extremity, pruritus, and somnolence. There is no mention of ototoxicity or auditory risks.
 

 4. **Nonclinical Toxicology (Section 13.2)**:
  - Studies with raxibacumab in rabbit, cynomolgus macaque, and human donor tissues showed no cross-reactivity with brain tissues, but there is no mention of ototoxicity or auditory risks.
 

 In summary, the drug label for Raxibacumab does not provide any information indicating that the drug is associated with or causes ototoxicity or auditory risks.",No,No,1,1
DOLUTEGRAVIR SODIUM,"The drug label for TIVICAY (dolutegravir) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The sections of the label that discuss adverse reactions, clinical trials, and postmarketing experiences do not include any references to ototoxicity or auditory issues. Therefore, there is no information in the provided drug label indicating that TIVICAY itself is associated with or causes ototoxicity risks or ototoxic reactions.",No,No,1,1
TRIFLUOPERAZINE HYDROCHLORIDE,"The provided drug label for Trifluoperazine Hydrochloride Tablets, USP does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. The label extensively covers various warnings, precautions, adverse reactions, and other safety information, but there is no specific reference to ototoxicity or auditory risks associated with the drug itself.
 

 To summarize:
 

 1. **General Warnings and Precautions**: The label discusses various risks such as tardive dyskinesia, neuroleptic malignant syndrome (NMS), and other side effects, but none of these sections mention ototoxicity or auditory risks.
 

 2. **Adverse Reactions**: The adverse reactions listed include drowsiness, dizziness, skin reactions, and neuromuscular reactions, among others, but there is no mention of ototoxicity or auditory issues.
 

 3. **Overdosage**: The symptoms and treatment of overdosage are described, focusing on extrapyramidal symptoms, CNS depression, and autonomic reactions, but again, no mention of ototoxicity.
 

 4. **Long-Term Therapy**: The section advises periodic evaluation for long-term therapy but does not mention auditory risks.
 

 In conclusion, the drug label for Trifluoperazine Hydrochloride does not associate the drug with ototoxicity or auditory risks.",No,No,1,1
METOPROLOL SUCCINATE,"The drug label for TOPROL-XL (metoprolol succinate) does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. The sections of the label that discuss adverse reactions, clinical trials, and post-marketing experiences do not include any references to ototoxicity or hearing-related issues. Therefore, based on the provided drug label, there is no indication that TOPROL-XL is associated with or causes ototoxicity or auditory risks.",No,No,1,1
GANAXOLONE,"The provided drug label for ZTALMY (ganaxolone) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the drug's indications, dosage, administration, warnings, precautions, adverse reactions, and other relevant information. 
 

 Here is a summary of the key sections reviewed for any mention of ototoxicity or auditory risks:
 

 1. **Indications and Usage**: No mention of ototoxicity or auditory risks.
 2. **Dosage and Administration**: No mention of ototoxicity or auditory risks.
 3. **Warnings and Precautions**: No mention of ototoxicity or auditory risks.
 4. **Adverse Reactions**: The adverse reactions listed include somnolence, pyrexia, salivary hypersecretion, and seasonal allergy, but there is no mention of ototoxicity or auditory risks.
 5. **Drug Interactions**: No mention of ototoxicity or auditory risks.
 6. **Use in Specific Populations**: No mention of ototoxicity or auditory risks.
 7. **Drug Abuse and Dependence**: No mention of ototoxicity or auditory risks.
 8. **Overdosage**: No mention of ototoxicity or auditory risks.
 9. **Clinical Pharmacology**: No mention of ototoxicity or auditory risks.
 10. **Nonclinical Toxicology**: No mention of ototoxicity or auditory risks.
 11. **Clinical Studies**: No mention of ototoxicity or auditory risks.
 12. **How Supplied/Storage and Handling**: No mention of ototoxicity or auditory risks.
 13. **Patient Counseling Information**: No mention of ototoxicity or auditory risks.
 14. **Medication Guide**: No mention of ototoxicity or auditory risks.
 15. **Instructions for Use**: No mention of ototoxicity or auditory risks.
 

 In conclusion, the drug label for ZTALMY does not associate the drug with ototoxicity or auditory risks, nor does it mention any ototoxic reactions caused by the drug.",No,No,1,1
ALLOPURINOL,"The provided drug label for ALOPRIM (allopurinol) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on other adverse reactions, such as skin rash, hypersensitivity, renal function impairment, hepatotoxicity, myelosuppression, and drowsiness. There is no information indicating that ALOPRIM itself is associated with or causes ototoxicity or auditory risks.",No,No,1,1
PENTOSAN POLYSULFATE SODIUM,"The drug label for ELMIRON® (pentosan polysulfate sodium) does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. The sections of the label that discuss adverse reactions, warnings, and precautions do not include any information about hearing loss, tinnitus, or other auditory issues directly associated with the drug. 
 

 Here is a summary of the relevant sections that might indirectly relate to sensory effects, but none of these explicitly mention ototoxicity:
 

 1. **Adverse Reactions**:
  - **Special Senses**: The label mentions ""tinnitus"" and ""optic neuritis"" under the category of special senses, but it does not explicitly state that these are caused by the drug. These are listed as adverse reactions observed during clinical trials or post-marketing experience.
 

 2. **Post-Marketing Experience**:
  - The label does not mention any auditory risks or ototoxic reactions reported during post-marketing surveillance.
 

 3. **Warnings and Precautions**:
  - The label primarily focuses on retinal pigmentary changes and increased bleeding risks but does not discuss any auditory risks or ototoxic reactions.
 

 In summary, the drug label for ELMIRON® does not provide any information indicating that the drug itself is associated with or causes ototoxicity or auditory risks. The mention of ""tinnitus"" under adverse reactions does not establish a direct causal relationship with the drug.",No,No,2,1
DEGARELIX,"The drug label for FIRMAGON (degarelix for injection) does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the provided drug label that discuss these specific adverse effects. Therefore, it can be concluded that the drug itself is not associated with or known to cause ototoxicity risks based on the information provided in the label.",No,No,1,1
OFLOXACIN OTIC,"### Summary of Ototoxicity and Auditory Risks for Ofloxacin Otic Solution 0.3%
 

 1. **General Precautions:**
  - **Cartilage and Joint Effects in Animals:** The systemic administration of quinolones, including ofloxacin, at doses much higher than those given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species. **(Not directly related to ototoxicity in humans, but indicates potential systemic risks at high doses.)**
 

 2. **Animal Studies:**
  - **Guinea Pig Study:** Young growing guinea pigs dosed in the middle ear with 0.3% Ofloxacin Otic Solution showed no systemic effects, lesions or erosions of the cartilage in weight-bearing joints, or other signs of arthropathy. No drug-related structural or functional changes of the cochlea and no lesions in the ossicles were noted in the guinea pig following otic administration of 0.3% ofloxacin for one month. **(No ototoxicity observed in animal studies with otic administration.)**
 

 3. **Pediatric Use:**
  - **Audiometric Testing in Pediatric Subjects:** No changes in hearing function occurred in 30 pediatric subjects treated with ofloxacin otic and tested for audiometric parameters. **(No ototoxicity observed in pediatric clinical trials.)**
 

 4. **Adverse Reactions:**
  - **Phase III Clinical Trials for Otitis Externa:** In the phase III clinical trials, there were single reports of transient loss of hearing and tinnitus. **(Isolated cases of auditory issues reported, but not conclusively linked to the drug.)**
 

 5. **Post-Marketing Adverse Events:**
  - **Neuropsychiatric Disturbances:** Cases of uncommon transient neuropsychiatric disturbances have been included in spontaneous post-marketing reports. A causal relationship with Ofloxacin Otic Solution 0.3% is unknown. **(No direct link to ototoxicity, but mentions neuropsychiatric disturbances.)**
 

 ### Conclusion:
 The drug label for Ofloxacin Otic Solution 0.3% does not provide conclusive evidence that the drug itself is associated with or causes ototoxicity. Animal studies and pediatric clinical trials did not show ototoxic effects. However, isolated cases of transient hearing loss and tinnitus were reported in clinical trials, and neuropsychiatric disturbances were noted in post-marketing reports, though a direct causal relationship with the drug was not established.",Less,No,1,1
METHAMPHETAMINE HYDROCHLORIDE,"The provided drug label for Desoxyn (methamphetamine hydrochloride) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label extensively covers various adverse effects, contraindications, warnings, and precautions, but there is no specific reference to ototoxicity or auditory risks associated with the use of Desoxyn.
 

 To summarize:
 

 - **Ototoxicity and Auditory Risks**: The drug label does not discuss any ototoxicity or auditory risks associated with Desoxyn.
 - **Ototoxic Reactions**: There are no mentions of ototoxic reactions caused by Desoxyn in the provided drug label.
 

 Therefore, based on the provided information, Desoxyn is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1
BLEOMYCIN,"The provided drug label for Bleomycin for Injection, USP does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on pulmonary toxicity, idiosyncratic reactions, integument and mucous membrane reactions, and other adverse effects such as vascular toxicities, fever, chills, vomiting, anorexia, weight loss, and pain at the tumor site. 
 

 To summarize:
 

 1. **Pulmonary Toxicity**: The label discusses pulmonary toxicity as a significant risk associated with bleomycin, including pneumonitis and pulmonary fibrosis. This is directly associated with the drug.
 

 2. **Idiosyncratic Reactions**: The label mentions severe idiosyncratic reactions in approximately 1% of lymphoma patients treated with bleomycin, including symptoms like hypotension, mental confusion, fever, chills, and wheezing. This is directly associated with the drug.
 

 3. **Integument and Mucous Membranes**: The label reports adverse reactions such as erythema, rash, striae, vesiculation, hyperpigmentation, and tenderness of the skin, among others. This is directly associated with the drug.
 

 4. **Other Adverse Reactions**: The label mentions vascular toxicities, Raynaud's phenomenon, fever, chills, vomiting, anorexia, weight loss, pain at the tumor site, phlebitis, and malaise. These are directly associated with the drug.
 

 Since the label does not mention ototoxicity or auditory risks, it can be concluded that there is no information provided in this label about bleomycin causing or being associated with ototoxicity or auditory risks.",No,No,1,1
VENLAFAXINE HCL,"The provided drug label for Venlafaxine HCL ER 150mg Capsules does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. The label covers a wide range of adverse reactions, warnings, and precautions, but there is no specific section or mention of ototoxicity (ear toxicity) or auditory risks (hearing-related issues) associated with the use of Venlafaxine HCL ER.
 

 To summarize:
 

 - **Ototoxicity and Auditory Risks**: The drug label does not discuss ototoxicity or auditory risks.
 - **Ototoxic Reactions**: There are no mentions of ototoxic reactions in the drug label.
 

 If you have concerns about ototoxicity or auditory risks related to Venlafaxine HCL ER, it is advisable to consult with a healthcare provider for more detailed information and personalized medical advice.",No,No,1,1
LECANEMAB,"The provided drug label for LEQEMBI (lecanemab-irmb) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the risks associated with Amyloid Related Imaging Abnormalities (ARIA), hypersensitivity reactions, and infusion-related reactions. There is no information indicating that LEQEMBI itself is associated with or causes ototoxicity or auditory risks.",No,No,1,1
BUPROPION HYDROCHLORIDE SR,"The drug label for Bupropion HCL ER (SR) does not explicitly mention ototoxicity or auditory risks as a primary concern. However, there are a few references to auditory-related adverse reactions:
 

 1. **Commonly Observed Adverse Reactions**:
  - **Tinnitus**: The label mentions that tinnitus occurred in at least 5% of subjects treated with bupropion hydrochloride extended-release tablets (SR) at both 300 mg/day and 400 mg/day doses, and at a rate at least twice the placebo rate. This indicates that the drug itself was associated with causing tinnitus.
 

 2. **Table 3. Adverse Reactions Reported by at Least 1% of Subjects and at a Greater Frequency than Placebo in Controlled Clinical Trials**:
  - **Tinnitus**: Tinnitus was reported in 6% of subjects taking 300 mg/day and 6% of subjects taking 400 mg/day, compared to 2% in the placebo group. This again indicates that the drug itself was associated with causing tinnitus.
 

 3. **Postmarketing Experience**:
  - **Deafness**: The label lists deafness as an adverse reaction identified during post-approval use of bupropion hydrochloride extended-release tablets (SR). This suggests that the drug itself was associated with causing deafness, although the frequency and causal relationship are not clearly established.
 

 In summary, the drug label indicates that bupropion hydrochloride extended-release tablets (SR) are associated with causing tinnitus and have been reported to cause deafness in postmarketing experience.",Less,Yes,1,1
BENAZEPRIL; BENAZEPRIL HYDROCHLORIDE,"The provided drug label for Benazepril does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label primarily focuses on the drug's indications, dosage, contraindications, warnings, precautions, adverse reactions, and pharmacokinetics. 
 

 Here is a summary of the relevant sections that might indirectly relate to ototoxicity or auditory risks, although none explicitly state that Benazepril itself is associated with or causes ototoxicity:
 

 1. **Adverse Reactions**:
  - The label lists various adverse reactions but does not mention any related to ototoxicity or auditory risks. The adverse reactions include headache, dizziness, somnolence, and postural dizziness, but these are not directly related to auditory function.
 

 2. **Warnings and Precautions**:
  - The label discusses several serious risks such as angioedema, anaphylactoid reactions, impaired renal function, hypotension, hyperkalemia, and hepatic failure. None of these warnings or precautions mention ototoxicity or auditory risks.
 

 3. **Drug Interactions**:
  - The label mentions interactions with diuretics, antidiabetics, NSAIDs, dual blockade of the renin-angiotensin system, mTOR inhibitors, lithium, and gold. None of these interactions are noted to cause ototoxicity or auditory risks.
 

 4. **Specific Populations**:
  - The label provides information on the use of Benazepril in pregnant women, nursing mothers, pediatric patients, geriatric patients, and patients with renal impairment. There is no mention of ototoxicity or auditory risks in these populations.
 

 5. **Pharmacodynamics and Pharmacokinetics**:
  - The label explains the mechanism of action and pharmacokinetics of Benazepril but does not mention any effects on auditory function or ototoxicity.
 

 In conclusion, the drug label for Benazepril does not associate the drug with ototoxicity or auditory risks. There are no explicit mentions or warnings about ototoxic reactions in the provided label.",No,No,1,1
FILGRASTIM,"The provided drug label for RELEUKO (filgrastim-ayow) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label includes detailed information on indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, and other clinical and pharmacological details, but there is no specific mention of ototoxicity or auditory risks associated with the use of RELEUKO.
 

 To summarize:
 - **Ototoxicity and auditory risks**: Not mentioned in the drug label.
 - **Ototoxic reactions**: Not mentioned in the drug label.
 

 Therefore, based on the provided drug label, RELEUKO is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1
VARENICLINE TARTRATE,"The provided drug label for CHANTIX (varenicline) does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. However, it does list various adverse reactions and side effects, including some related to the ear and auditory system. Here is a summary of the relevant parts:
 

 1. **Ear and Labyrinth Disorders**:
  - **Infrequent**: tinnitus, vertigo.
  - **Summary**: Tinnitus and vertigo were reported infrequently in patients taking CHANTIX. The label does not explicitly state that CHANTIX caused these conditions, but they were observed during clinical trials.
 

 2. **Rare**: deafness, Meniere's disease.
  - **Summary**: Deafness and Meniere's disease were reported rarely in patients taking CHANTIX. Again, the label does not explicitly state that CHANTIX caused these conditions, but they were observed during clinical trials.
 

 3. **Nervous System Disorders**:
  - **Infrequent**: balance disorder.
  - **Summary**: Balance disorder was reported infrequently in patients taking CHANTIX. The label does not explicitly state that CHANTIX caused this condition, but it was observed during clinical trials.
 

 In summary, while the drug label for CHANTIX lists tinnitus, vertigo, deafness, Meniere's disease, and balance disorder as adverse reactions, it does not explicitly state that CHANTIX caused these conditions. These conditions were observed during clinical trials and postmarketing experience.",Less,No,1,1
MILRINONE LACTATE,"The drug label for Milrinone Lactate Injection, USP does not mention ototoxicity, auditory risks, or ototoxic reactions. There are no sections or sentences in the provided drug label that discuss these specific concerns. Therefore, based on the provided information, Milrinone Lactate Injection, USP is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1
LITHIUM,"The drug label for Lithium Oral Solution discusses ototoxicity and auditory risks in the following sections:
 

 1. **Section 5.1 Lithium Toxicity**:
  - **Sentence**: ""Neurological signs of lithium toxicity range from mild neurological adverse reactions such as fine tremor, lightheadedness, lack of coordination, and weakness; to moderate manifestations like giddiness, apathy, drowsiness, hyperreflexia, muscle twitching, ataxia, blurred vision, tinnitus, and slurred speech; and severe manifestations such as clonus, confusion, seizure, coma, and death.""
  - **Summary**: The drug itself is associated with ototoxicity risk, specifically mentioning tinnitus as a moderate manifestation of lithium toxicity.
 

 2. **Section 6 Adverse Reactions**:
  - **Sentence**: ""Central Nervous System: tremor, muscle hyperirritability (fasciculations, twitching, clonic movements of whole limbs), hypertonicity, ataxia, choreoathetotic movements, hyperactive deep tendon reflexes, extrapyramidal symptoms including acute dystonia, cogwheel rigidity, blackout spells, epileptiform seizures, slurred speech, dizziness, vertigo, downbeat nystagmus, incontinence of urine or feces, somnolence, psychomotor retardation, restlessness, confusion, stupor, coma, tongue movements, tics, tinnitus, hallucinations, poor memory, slowed intellectual functioning, startled response, worsening of organic brain syndromes, myasthenic syndromes (rarely).""
  - **Summary**: The drug itself is associated with ototoxicity risk, specifically mentioning tinnitus and vertigo as adverse reactions.
 

 3. **Medication Guide**:
  - **Sentence**: ""Stop taking lithium oral solution and call your healthcare provider right away if you have any symptoms of lithium toxicity including: ... ringing in your ears.""
  - **Summary**: The drug itself is associated with ototoxicity risk, specifically mentioning ringing in the ears (tinnitus) as a symptom of lithium toxicity.
 

 In summary, the drug label for Lithium Oral Solution indicates that the drug itself is associated with ototoxicity risks, particularly mentioning tinnitus and vertigo as potential adverse reactions.",Most,Yes,1,1
QUETIAPINE FUMARATE,"The provided drug label for SEROQUEL XR (quetiapine fumarate) does not explicitly mention ototoxicity, auditory risks, or ototoxic reactions. The label includes extensive information on various adverse reactions, warnings, precautions, and clinical studies, but there is no specific reference to ototoxicity or auditory risks associated with the use of SEROQUEL XR.
 

 To summarize:
 

 1. **Warnings and Precautions**: The label does not list ototoxicity or auditory risks under the warnings and precautions section.
 2. **Adverse Reactions**: The adverse reactions section does not mention any ototoxic reactions or auditory risks.
 3. **Clinical Studies**: The clinical studies section does not report any findings related to ototoxicity or auditory risks.
 4. **Postmarketing Experience**: The postmarketing experience section does not include reports of ototoxicity or auditory risks.
 

 In conclusion, the drug label for SEROQUEL XR does not associate the drug with ototoxicity or auditory risks. There are no mentions or discussions of ototoxic reactions in the provided label.",No,No,1,1
PROMETHAZINE HYDROCHLORIDE TABLET,"The provided drug label for Promethazine Hydrochloride does not explicitly mention ototoxicity or auditory risks and ototoxic reactions. The label primarily focuses on the drug's general pharmacology, indications, contraindications, warnings, precautions, adverse reactions, and dosage information. 
 

 Here is a summary of the relevant sections that might indirectly relate to auditory risks, though they do not specifically mention ototoxicity:
 

 1. **Adverse Reactions - Central Nervous System**:
  - ""Tinnitus"" is listed as a possible adverse reaction. 
  - **Summary**: Tinnitus (ringing in the ears) is mentioned as a potential adverse reaction, but the label does not explicitly state that Promethazine Hydrochloride causes ototoxicity.
 

 2. **Overdosage**:
  - ""Tinnitus"" is also mentioned as a symptom of overdosage.
  - **Summary**: Tinnitus is noted as a symptom of overdosage, but again, there is no direct mention of ototoxicity caused by the drug.
 

 In conclusion, the drug label does not provide specific information about ototoxicity or auditory risks directly associated with Promethazine Hydrochloride. The only related mention is tinnitus, which is listed as a potential adverse reaction and a symptom of overdosage, but there is no explicit connection to ototoxicity.",Less,No,1,1
FENOFIBRATE,"The provided drug label for ANTARA (fenofibrate) does not mention ototoxicity, auditory risks, or ototoxic reactions. The label extensively covers various aspects such as indications, dosage, contraindications, warnings, precautions, adverse reactions, and pharmacology, but there is no specific information related to ototoxicity or auditory risks associated with the use of ANTARA.
 

 To summarize:
 - **Ototoxicity and auditory risks**: The drug label does not discuss any ototoxicity or auditory risks.
 - **Ototoxic reactions**: There are no mentions of ototoxic reactions caused by ANTARA in the provided drug label.
 

 Therefore, based on the provided information, ANTARA (fenofibrate) is not associated with or reported to cause ototoxicity or auditory risks.",No,No,1,1